Gene-Targeted Drug Tagrisso Cuts Death Rate in Half for Patients With Early-Stage Lung Cancer
TUESDAY, June 6, 2023 (HealthDay News) — Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical trial shows. The results could have major implications for patients whose cancers carry a mutationContinue Reading